許多天然且營養性的治療被認為是輔助治療，並且研究方向並非針對他們對腫瘤的直接功效，反而是著重於預防或回轉癌症治療相關副作用以及增進生活品質上的益處。因此AVEMAR在乳癌、肺癌、及頭頸癌上也進行了一些這方面的相關研究。
在乳癌的生活品質研究上，五十五名平均屬於UICC第一到四期的個案參與此項研究並持續追蹤三十二點二個月，並根據 EORTC QLQ-C 30 問卷作調查。結果顯示病患的生理機能、心理機能、及整體健康狀況皆有顯著改善；疲勞、噁心、嘔吐、失眠、便秘等症狀則減輕。此外落髮現象及止吐劑和鎮定劑的需求量也降低。這些成效在開始使用AVEMAR三個月後即顯現，並且能維持到整個觀察期結束。
AVEMAR對於肺癌方面，曾在十六位病患進行一個小規模的生活品質研究測試。這十六位患者男女各半，其中七位是罹患小細胞肺癌（ SCLC ）而九位是腺癌，且大部分患者已接受化學或放射線治療。使用AVEMAR十二週後，他們的整體健康狀況、社交機能及疲倦症狀皆有顯著的改善，並且對於情緒上及胃口上也似乎有改善趨勢。
另外五十五名主要罹患喉頭及咽喉癌（包括數個唾液腺及軟組織病例）的患者也使用AVEMAR。使用後他們的生活品質也獲得改善（例如惡性症狀舒緩，體重增加）。五個唾液腺腫瘤患者甚至長期不再有腫瘤。這些實驗結果皆為AVEMAR使用於癌症治療上提供很好的支持。
Many natural and nutritional therapies are regarded as supportive therapies, and are not studied for their direct effect on tumors, but instead for benefits in terms of preventing or reversing cancer therapy related side effects and improving quality of life. Several studies of this type have been conducted with Avemar.
Breast Cancer
While no clinical study on the anti-tumor effect of Avemar was conducted for breast cancer, there was an open quality-of-life study performed at the University of Szeged's Clinic of Surgery by Professor Adam Balogh. 55 individuals were enrolled in the study, with a mean age of 55.4 years and an average follow-up period of 32.2 months The study was based on an EORTC QLQ-C 30 questionnaire. The patient's clinical stage was not a criterion for inclusion, UICC stages I-IV being represented in an almost even distribution. Less than half of patients received simultaneous chemotherapy and/ or radiotherapy.
The patients showed significant improvement in physical function (p<0.05), emotional functions (p<0.001), and global state of health (p<0.01); while the following parameters were considerably reduced: fatigue (p<0.01), nausea and vomiting (p<0.01), insomnia (p<0.01), and constipation(p<0.01). Other parameters not indicated in EORTC-QLQ C30 questionnaire were: hair loss (p<0.001), antiemetic consumption (p<0.001), use of tranquillizers (p<0.05). The indicated effects manifested themselves within 3 months of beginning treatment and were maintained during the whole observation period (Balogh, 2001).
TOP
Lung Cancer
While the anti-tumor effect of Avemar was not tested for lung cancer, a pilot study aimed at investigating it influence on quality of life was conducted on 16 patients (8 male, 8 female, 7 small cell lung cancer (SCLC) and 9 adenocarcinoma). The majority of patients were treated with chemo/radiotherapy. During a mean observation period of 8 ± 2 months a self-control test using an EORTC QLQ-C30 questionnaire was conducted. Following treatment with Avemar for 12 weeks, a significant improvement was achieved in the global state of health, social functions and fatigue, with a more modest non-significant positive trend in mood and appetite parameters. The effect on fatigue is of primary importance, although major conclusions, owing to the low number of patients tested, can not be drawn (Hidvegi et al., 2003).
TOP
Hand and Neck Cancers
55 patients suffering predominantly from tumors of the larynx and pharynx (as well as several salivary gland and soft tissue cases) were treated with Avemar. The quality of life improved (relief of cachectic symptoms, increase of body weight). Five salivary gland tumor patients remained tumor free on a long-term basis. The results inferred that the relief of cachectic symptoms and increase in body weight can be explained to a certain extent by mechanisms already known, but, in any case, provide, along with its QOL effects, good reasons for using Avemar in oncotherapy (Sukkar et al., 2006).
TOP
